MICROMEDEX, a part of The Thomson Corporation (TSX: TOC; NYSE: TOC), announced today the expansion of a popular drug information product available to clinicians through mobileMICROMEDEX™. Information on more than 3,200 drugs was expanded to include additional data, making this information the most clinically relevant available via a handheld device.

"We are currently undertaking an exciting project that will help us quickly respond to clinician’s information needs by creating the content they want," said Michael Soares, vice president of editorial for MICROMEDEX. "Here is a great example—our customers asked for these enhancements, and we were able to react quickly to meet their request."

The new information now available in mobileMICROMEDEX includes:

• Precaution information allowing clinicians to reference populations that may use a particular drug with caution.
  
• Drug monitoring information enabling clinicians to quickly reference necessary lab tests and potential signs and symptoms to watch for when a patient is prescribed a particular drug.
  
• Recommended doses for patients requiring dose adjustments permitting clinicians to reference dosing for special populations such as pediatrics, geriatrics, or those with hepatic insufficiency, etc.
  
• Indications now divided by "FDA labeled" and "non-FDA labeled" reassuring clinicians about their decision to use a drug for a particular indication.
  
• Adverse effects separated into "common" and "serious" helping clinicians to make more informed decisions as to how to handle an adverse reaction.

This enhancement is also available to MICROMEDEX^® Healthcare Series customers through personal computer applications.For detailed information about mobileMICROMEDEX™, call IScientia +32(2) 481 60 40 or email to info@iscientia.com